What Can You Expect at the Definitive TPD Forum in 2025?
Providing unparalleled networking opportunities with 450+ academic KOLs, start-ups, experienced biotechs, large pharma and leading solution providers, this year’s TPD & Induced Proximity Summit returns with a brand-new and refreshed program featuring the latest data, the newest innovators and key KOLs in the field including Craig Crews and Ray Deshaies.
This is your ultimate forum to take advantage of key networking opportunities, strategize your therapeutic’s journey to the clinic, and successfully bring PROTACS, molecular glues, and new induced proximity modalities to the standard-of-care for patients in need.
Brand New Companies for 2025
Divide & Conquer the TPD World
The TPD field is vast, which is why we have meticulously researched with subject matter experts to identify the key challenges facing the community, including PROTAC leaders, glue hunters, novel ligase experts and non-degrading proximity innovators. There are many hurdles, but together we can tackle them.
By splitting into 8 curated content streams, our speakers have the chance to deliver tailored presentations to dive into specific challenges for each area. Bring along members of your team across the drug pipeline, and you can be sure you’ve left no stone unturned.
Key Speakers, Companies & Content Tracks
Discovery Track
This track will showcase novel cutting-edge platforms designed to unlock novel, previously undruggable targets, supported by rich in vitro and cell-based assay data.
Attendees will gain a comprehensive view of the next wave of degraders and actionable insights into accelerating discovery.
This track is for you if: You’re in the screening, hit-finding or hit-to-lead stage.
Speaking Companies Include:
Pre-Clinical Development Track
This track will highlight the most promising degrader candidates advancing through in vivo validation and lead optimization across oncology, inflammatory and CNS indications. Talks will feature mouse model data, giving attendees a clear picture of how TPD is translating into novel cures for unmet diseases areas.
This track is for you if: You’re lead optimizing for oral bioavailability, PKPD, efficacy or safety.
Speaking Companies Include:
Translational & Clinical Development Track
This track will cover the latest translational and clinical data across degraders targeting oncology, autoimmune and CNS indications. Talks will cover how a wide breadth of mechanisms – from PROTACs to DACs and AUTOTACs– are showing meaningful patient outcomes and trailblazing the way for TPD.
This track is for you if: You’re putting together a pre-clinical package or in the clinic.
Speaking Companies Include:
Unmissable Agenda Highlights
New Frontiers & Mechanistic Day | Monday, October 27
Kickstarting the week, the New Frontiers & Mechanistic Day will provide a comprehensive foundation for attendees at every stage of the TPD journey. Whether you're building your degrader discovery toolkit at TPD 101: Tools & Technologies Day, gaining strategic insight at the Strategic Design Principles Workshop, or exploring the cutting-edge science emerging from academia at the New Academic Frontiers Day, you'll be equipped with the knowledge and context to make the most of the main conference.
New Academic Frontiers Day
Key Highlights:
A Glue Here, A TAC There: Induced Proximity as a Drug Modality
- Craig Crews, John C. Malone Professor of Molecular, Cellular, & Developmental Biology, Yale University
Unveiling the Hidden Interactome of CRBN Molecular Glues with Chemoproteomics
- Katherine Donovan, Lead Scientist & Managing Director, Fischer Labs Dana Farber Cancer
There is More Than One Ligase for Each Target & We Know It
- Victor Guallar, ICREA Professor, Barcelona Supercomputing Center
TPD 101: Tools & Technology Day
Key Highlights:
Optimizing Drug Discovery with the Development of an Ultra High Throughput, Lysate-Compatible Induced Proximity Screening Systemy
- Zachary Rosenthal, Founder & Chief Executive Officer, Birdwood Therapeutics
A Pursuit of the Development of Non-Degrader Molecular Glues Targeting Different Protein Complexes
- Derek Taylor, Head of Structural Biology, Rappta Therapeutics & Professor, Case, Western Reserve University
Accelerating Molecular Glue Discovery with CBM/PDL Platforms for Novel Target Engagement
- Dong Seok Kim, Chief Executive Officer, Aevis Bio
Strategic Design Principles Workshop Day
Discover Ligase-Target Pairings to Enable Rational Molecular Glue Drug Design
- Arnout Schepers, Chief Executive Officer, TenAces Bio
- Chris Tame, Founder & Chief Executive Officer, Ternary Therapeutics
- Randolph Lopez, Chief Technology Officer, A-Alpha Bio
When to Use TPD: Ensuring Your Degrader is the Best-in-Class Approach to Drug Your Target
- Matthew Sowa, Vice President of Lead Discovery, C4 Therapeutics
- Jack Carter, Director of Biology & Pharmacology, Prelude Therapeutics
- Yong Cang, Chief Scientific Officer, Degron Therapeutics
Developing Efficient & Dependable TPD Design Principles
- Brent Meadows, Chief Business Officer, Polymed Biopharma
- Esther Lee, Associate Director of Medicinal Chemistry, AstraZeneca
- Prakash Palde, Director of Biophysics & High-Throughput Screening, Pfizer
Future of TPD & Induced Proximity Day | Thursday October, 30
Capping off the summit, the Future of TPD & Induced Proximity Day dives deeper into specialized areas pushing the boundaries of the field. Join the 2nd Next Generation Protein Modulation Day to explore novel induced proximity approaches beyond PROTACs, and the Novel Ligases–Targeted Drug Discovery Day to unlock the potential of E3 ligases beyond Cereblon and VHL.
Next-Generation Protein Modulation Day
Panel Discussion: Exploring the Frontier Beyond Traditional Degradation: Challenges, Opportunities & Emerging Modalities
- Simon Glerup, Co-founder & Chief Scientific Officer, Draupnir Bio
- Maureen Galmes-Spit, Vice President of Research, Laigo Bio
- Scott Kanner, Co-founder & Associate Director of Platform Sciences, Stablix
- Rene Lemieux, Head of Drug Discovery Sciences, Avilar Therapeutics
Sequence-Selective Translation Inhibition as a Novel, ProximityBased Small Molecule Therapeutic Modality
- Lawrence Hamann, Co-founder & Chief Executive Officer, Interdict Bio
Development of Oral ATAC Degraders for Extracellular Proteins
- Rene Lemieux, Head of Drug Discovery Sciences, Avilar Therapeutics
Novel Ligase-Targeted Drug Discovery Day
Panel Discussion: Beyond CRBN & VHL: Harnessing Novel Ligases for Next-Gen Drug Discovery
- Zoran Rankovic, Director of Center for Protein Degradation, Institute of
Cancer Research - Arnout Schepers, Chief Executive Officer, TenAces Bio
- Nicki Thompson, Chief Executive Officer, TrimTech Therapeutics
- Benedict Cross, Chief Technology Officer, Phoremost
Novel Molecular Glue Degraders of P300 & Mechanistic Characterization of Determinants of Selectivity Over Closely Related Paralog CBP
- Adam Davenport, Chief Development Officer, Proxygen
Harnessing the Innate Properties of Novel E3 Ligase Trim21 for the Development of Treatments for Neurodegenerative Diseases
- Nicki Thompson, Chief Executive Officer, TrimTech Therapeutics
Explore the Full Event Guide
- 80+ World Class Speakers
- 4 Days of Exclusive Data-Driven TPD Content
- CXO and VC Panel Discussions
- Bespoke Networking & Partnering Opportunities
- The World’s Leading Event for the TPD & Induced Proximity Industry
Explore the Agenda
Hear the latest industry breakthroughs and gain exclusive insights on the TPD innovations during our packed agenda, interactive roundtables, and new CCOs & VC panel discussions.
Partner With Us
Position yourself alongside as the leading solution provider to ensure your brand is at the heart of TPD biopharma deals.
Join Biopharma Experts
Be part of the hottest conversations with like-minded attendees spanning all stages of drug development and make critical connections during our dedicated networking sessions.